Jasper Therapeutics Inc (JSPR) - Total Liabilities
Based on the latest financial reports, Jasper Therapeutics Inc (JSPR) has total liabilities worth $17.78 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Jasper Therapeutics Inc (JSPR) investment intensity to see how much of total assets are deployed in long-term investments.
Jasper Therapeutics Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Jasper Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Jasper Therapeutics Inc's balance sheet.
Jasper Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Jasper Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Invoicery Group AB
ST:FRILAN
|
Sweden | Skr223.29 Million |
|
Uniserve Communications Corp
V:USS
|
Canada | CA$11.22 Million |
|
HiTi Digital Inc
TW:3494
|
Taiwan | NT$1.18 Billion |
|
Pergamon Status Dis Ticaret AS
IS:PSDTC
|
Turkey | TL4.93 Billion |
|
BRIDGETEC Corp
KQ:064480
|
Korea | ₩11.50 Billion |
|
Garden Stage Limited Ordinary Shares
NASDAQ:GSIW
|
USA | $17.70 Million |
|
Philippos Nakas S.A
AT:NAKAS
|
Greece | €12.43 Million |
|
TAG Oil Ltd.
V:TAO
|
Canada | CA$2.43 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Jasper Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See JSPR equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.26 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.23 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jasper Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jasper Therapeutics Inc (2019–2025)
The table below shows the annual total liabilities of Jasper Therapeutics Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $31.63 Million | +73.54% |
| 2024-12-31 | $18.23 Million | +10.78% |
| 2023-12-31 | $16.45 Million | +32.98% |
| 2022-12-31 | $12.37 Million | -48.74% |
| 2021-12-31 | $24.14 Million | -58.73% |
| 2020-12-31 | $58.49 Million | +857.39% |
| 2019-12-31 | $6.11 Million | -- |
About Jasper Therapeutics Inc
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commerci… Read more